Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, Inc. (Nasdaq: SPRO) has appointed Satyavrat “Sath” Shukla as Chief Financial Officer, starting January 4, 2021. Shukla, with over 20 years of experience, previously served as CFO at Ziopharm Oncology and held significant roles at Vertex Pharmaceuticals. His expertise will support Spero's growth, particularly with the commercialization of tebipenem HBr and ongoing clinical trials for SPR720 and SPR206. The board has approved a stock option grant of 75,000 shares to Shukla as part of his inducement to join the company.
Spero Therapeutics (Nasdaq: SPRO) announced its addition to the NASDAQ Biotechnology Index (NBI), effective December 21, 2020. The NBI tracks biotechnology and pharmaceutical securities and serves as a benchmark for various ETFs. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. The company's lead product, tebipenem HBr, is the first oral carbapenem antibiotic for complicated urinary tract infections, with positive Phase 3 trial results announced in September 2020. Spero is also advancing other therapies for rare diseases.
Spero Therapeutics (Nasdaq: SPRO) has initiated dosing in a Phase 2a clinical trial of SPR720 for nontuberculous mycobacterial pulmonary disease (NTM-PD), targeting unmet medical needs. The trial will enroll ~90 patients, comparing SPR720 (500 mg or 1,000 mg) against placebo and standard care over 28 days. SPR720 shows promise as a first oral antibiotic for NTM-PD, with top-line data expected in H1 2022. It has orphan drug and Qualified Infectious Disease Product designations from the FDA, enhancing its market potential against increasing instances of drug-resistant infections.
Spero Therapeutics announced the appointment of Tamara Joseph as Chief Legal Officer effective December 2, 2020. Joseph brings over 20 years of experience in the biotechnology sector, having held leadership roles in various companies. Her expertise will support Spero in moving towards the potential commercialization of tebipenem HBr, which has shown positive results in clinical trials. The company's lead product, tebipenem HBr, is aimed at treating complicated urinary tract infections. A non-qualified stock option for 75,000 shares was granted to Joseph as part of her inducement to join.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on November 30, 2020, the grant of non-qualified stock options for 76,200 shares to ten new employees under its 2019 Inducement Equity Incentive Plan. The options, with an exercise price of $16.57 per share, incentivize new hires aligned with Nasdaq Listing Rule 5635(c)(4). Each option will vest over four years, with 25% vesting after the first year and the remainder monthly. Spero focuses on treatments for multi-drug resistant infections and rare diseases, such as its lead candidate, tebipenem HBr, which showed positive results in a Phase 3 trial.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced that CEO Ankit Mahadevia, M.D. will participate in a fireside chat at the 3rd Annual Evercore ISI HealthCONx Conference from December 1-3, 2020. The presentation will take place on December 3, 2020, from 8:25 to 8:45 AM ET. Interested parties can access the live webcast on Spero's website under the 'Events and Presentations' section, with replays available for 90 days post-event. Spero focuses on developing treatments for multi-drug resistant infections and rare diseases, including its lead candidate, tebipenem HBr, which is in late-stage clinical trials.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced significant progress in its ADAPT-PO Phase 3 trial, achieving its primary endpoint for oral tebipenem HBr in treating complicated urinary tract infections. Financial results for Q3 2020 reported a net loss of $18.9 million on $4 million revenue. The company maintains cash reserves of $127.2 million, expected to fund operations into Q1 2022. Upcoming milestones include an NDA submission for tebipenem HBr by Q2 2021 and the initiation of a Phase 2a trial for SPR720 by year-end 2020. Spero also prepares for upcoming investor presentations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on November 3, 2020, that its Compensation Committee granted stock options to purchase 30,000 shares to three new hires under the 2019 Inducement Equity Incentive Plan. These options, with an exercise price of $13.11 per share, vest over four years, incentivizing employees to enhance the company's multi-asset biopharmaceutical initiatives. Spero is focused on developing treatments for multi-drug resistant infections and rare diseases, with ongoing projects like tebipenem HBr and SPR720.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on November 5, 2020, at 4:30 p.m. EST to discuss its third quarter 2020 financial results and business updates. The company is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero's lead candidate, tebipenem HBr, showed positive results in its Phase 3 ADAPT-PO trial for complicated urinary tract infections. Additionally, Spero is advancing SPR720 for rare pulmonary diseases and SPR206 for multi-drug resistant infections in hospitals.
Spero Therapeutics (Nasdaq: SPRO) announced 15 data presentations at IDWeek™ 2020, taking place virtually from October 21-25, 2020. Key topics include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial for tebipenem HBr, which showed non-inferiority to IV ertapenem for treating complicated urinary tract infections (cUTI). Other presentations cover Spero's pipeline products, including SPR720 and SPR206. The company aims to advance antibacterials targeting multi-drug resistant infections and plans to submit a New Drug Application for tebipenem HBr in Q2 2021.
